DEA Erases Gas-Station Opioids in Four Days — and Erases an Off-Ramp Some People Were Actually Using

Four days from now, a compound sold at vape shops and gas stations under a name locals gave it themselves — gas station heroin — becomes a Schedule I narcotic, the same legal category as heroin. Good. It should have happened two years ago.

Scheduling concentrated 7-OH is the right call, and it will also force withdrawal onto people the healthcare system already failed once.

Here’s what’s actually getting banned. 7-hydroxymitragynine — 7-OH — occurs naturally in kratom leaf, but only as a trace player, well under 2% of the plant’s total alkaloid content. Left in the leaf, it’s minor. Extracted and concentrated into powders, tablets, gummies, and, per the FDA’s own warning, even ice cream cones, it becomes something else: a compound that hits the same mu-opioid receptor as morphine and fentanyl — the switch in the brain that kills pain, produces euphoria, and at high enough doses stops you breathing — and hits it harder. Lab comparisons have clocked isolated 7-OH at roughly 13 times more potent than morphine at that receptor, with more than triple morphine’s respiratory-depression risk. Leaf: mostly fine. Syringe-strength extract sold next to the beef jerky: not fine.

The DEA’s July 1 Notices of Intent target exactly that gap — 7-OH above a 0.050% concentration threshold, plus three synthetic relatives — while explicitly carving out natural leaf and powder. DEA Administrator Terrance Cole framed it as action against “highly concentrated, synthetic 7-OH products, which pose a growing threat to public safety and health.” HHS Secretary Robert F. Kennedy Jr. was blunter, calling the compounds “dangerous opioids that fuel addiction and put American lives at risk,” in a joint HHS-FDA statement. Partnership for a Drug-Free New Jersey’s Angelo Valente backed the move for the reason that should worry anyone who’s bought one of these products: consumers, he said in a statement supporting the action, “often have no reliable way of knowing the potency, purity or actual contents of the products they purchase.”

All true. None of it changes what’s happening at the Packard Health Clinic in Ann Arbor, where patients started showing up in July — not because they’d hit bottom, but because vape shop clerks told them the product was disappearing in August. Some weren’t chasing a high. They were using 7-OH for pain, for anxiety, for opioid withdrawal itself, because it was legal, cheap, and open at 2 a.m. when nothing else was. The comment period on this rule closed yesterday. The earliest the order can take effect is August 5. That’s not a runway. That’s a long weekend for anyone whose entire treatment plan was a gas station shelf.

The industry will sue, arguing DEA fast-tracked emergency scheduling on a product line that’s been sold openly for two years — the same argument made over xylazine. They might even win that argument on process.

They will not be making it on behalf of the person right now counting how many packets are left before Wednesday.